Guardant Health, Inc. (NASDAQ:GH) Given Average Recommendation of “Buy” by Analysts

Shares of Guardant Health, Inc. (NASDAQ:GH) have been given a consensus recommendation of “Buy” by the fifteen ratings firms that are presently covering the company, MarketBeat reports. Fifteen equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $40.60.

GH has been the subject of a number of recent analyst reports. Leerink Partners lowered their target price on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. The Goldman Sachs Group lifted their price objective on shares of Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. UBS Group upped their target price on Guardant Health from $32.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, August 21st. JPMorgan Chase & Co. raised their target price on Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Finally, Sanford C. Bernstein dropped their price target on Guardant Health from $40.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 30th.

Insider Activity

In other news, Director Meghan V. Joyce sold 2,896 shares of Guardant Health stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total value of $86,590.40. Following the sale, the director now directly owns 7,648 shares of the company’s stock, valued at $228,675.20. The trade was a 27.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 5.50% of the company’s stock.

Institutional Trading of Guardant Health

Several large investors have recently bought and sold shares of the business. Wellington Management Group LLP boosted its stake in Guardant Health by 188.6% during the third quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company’s stock worth $232,325,000 after buying an additional 6,618,785 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Guardant Health by 1,282.5% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company’s stock worth $28,128,000 after acquiring an additional 1,137,482 shares during the period. ARK Investment Management LLC boosted its position in shares of Guardant Health by 233.5% during the 3rd quarter. ARK Investment Management LLC now owns 1,512,694 shares of the company’s stock valued at $34,701,000 after acquiring an additional 1,059,104 shares during the last quarter. Erste Asset Management GmbH purchased a new stake in shares of Guardant Health in the third quarter valued at about $21,389,000. Finally, Lord Abbett & CO. LLC purchased a new stake in shares of Guardant Health in the third quarter valued at about $15,624,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Down 0.5 %

Guardant Health stock opened at $34.76 on Monday. The company has a quick ratio of 5.85, a current ratio of 6.22 and a debt-to-equity ratio of 16.70. The firm has a market cap of $4.29 billion, a P/E ratio of -8.20 and a beta of 1.26. The business has a fifty day moving average of $27.92 and a two-hundred day moving average of $28.16. Guardant Health has a twelve month low of $15.81 and a twelve month high of $38.53.

Guardant Health (NASDAQ:GH) last announced its earnings results on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The firm had revenue of $191.48 million during the quarter, compared to the consensus estimate of $170.49 million. During the same quarter in the prior year, the firm posted ($0.73) earnings per share. The business’s revenue for the quarter was up 33.9% compared to the same quarter last year. On average, analysts forecast that Guardant Health will post -3.44 earnings per share for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.